Vertical Pharms patent expiration
1. Dsuvia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10507180 | VERTICAL PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(2 years from now) | |
| US8535714 | VERTICAL PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(2 years from now) | |
| US8778394 | VERTICAL PHARMS | Small-volume oral transmucosal dosage forms |
Jan, 2027
(2 years from now) | |
| US10245228 | VERTICAL PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(2 years from now) | |
| US10342762 | VERTICAL PHARMS | Small-volume oral transmucosal dosage forms |
Jan, 2027
(2 years from now) | |
| US8252328 | VERTICAL PHARMS | Bioadhesive drug formulations for oral transmucosal delivery |
Jan, 2027
(2 years from now) | |
| US8778393 | VERTICAL PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(2 years from now) | |
| US9320710 | VERTICAL PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(2 years from now) | |
| US8226978 | VERTICAL PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(2 years from now) | |
| US8865211 | VERTICAL PHARMS | Bioadhesive drug formulations for oral transmucosal delivery |
Jan, 2027
(2 years from now) | |
| US8231900 | VERTICAL PHARMS | Small-volume oral transmucosal dosage |
Jan, 2027
(2 years from now) | |
| US9744129 | VERTICAL PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Jan, 2027
(2 years from now) | |
| US8252329 | VERTICAL PHARMS | Bioadhesive drug formulations for oral transmucosal delivery |
Jan, 2027
(2 years from now) | |
| US11676691 | VERTICAL PHARMS | Storage and dispensing devices for administration of oral transmucosal dosage forms |
Mar, 2030
(5 years from now) | |
| US10896751 | VERTICAL PHARMS | Storage and dispensing devices for administration of oral transmucosal dosage forms |
Mar, 2030
(5 years from now) | |
| US8574189 | VERTICAL PHARMS | Storage and dispensing devices for administration of oral transmucosal dosage forms |
Mar, 2030
(5 years from now) | |
| US8202535 | VERTICAL PHARMS | Small-volume oral transmucosal dosage forms |
Oct, 2030
(6 years from now) | |
| US8865743 | VERTICAL PHARMS | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
Oct, 2030
(6 years from now) | |
| US8945592 | VERTICAL PHARMS | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
Jul, 2031
(6 years from now) | |
| US11672738 | VERTICAL PHARMS | Apparatus and methods for dispensing oral transmucosal dosage forms |
Feb, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 02, 2021 |
Drugs and Companies using SUFENTANIL CITRATE ingredient
Market Authorisation Date: 02 November, 2018
Treatment: Treatment of acute pain
Dosage: TABLET
More Information on Dosage
DSUVIA family patents
